Artelo Biosciences Q3 net loss narrows as expenses fall
ARTL•Artelo Biosciences’ third-quarter net loss narrowed year over year to $1.80 million as research and development and general and administrative expenses declined.
1. Quarterly results
Artelo Biosciences reported a third-quarter net loss of $1.80 million, which narrowed year over year as research and development and general and administrative expenses fell.
2. Pipeline updates
The company initiated a second Phase 2 study of ART27.13 in glaucoma and is enrolling patients in the DREAM trial. It plans to start a Phase 1 multiple ascending dose study of ART26.12 for pain in the fourth quarter of 2026. Artelo also cited nonclinical findings showing significant weight loss in animal models for ART27.13, supporting expanded development in obesity.
